![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Entry tags:
Снижающаяся эффективность вакцин - Пуэрто-Рико
Согласно данным анализа заболеваемости ковидом привитых тремя разными типами вакцин в стране, начальная эффективность ( вскоре после формирования иммунитета, 2 недели для мРНК вакцин и 32 дня со дня прививки - для векторной) была 90% для "модерны" (mRNA-1273), 87% для "файзера" (BNT162b2) и 58% для "джансена" ( Ad26.COV2.S).
Спустя 4 месяца после прививки, защитная эффективность от болезни составляла уже 71%, 56%, и 27%, соответственно.
Менее всего прививка (любая, но слабее всех-джансен) защищала тех, кому более 85 лет.
При этом, все вакцины все же, более эффективно предотвращали госпитализацию (примерно в 9 раз, по сравнению с непривитыми) и смерть (примерно в 14 раз) от ковида, даже спустя 4 месяца после вакцинации. Данные цифры усреднены (актуальные цифры- в самой статье), тк джанссен показала чуть меньшую эффективность, и для более пожилых тоже защита чуть ниже.
Так же, с точки зрения авторов, защитная эффективность слабела не только потому, что было широкое распространение "дельты" (тк вначале доминирования дельты защита была выше чем в конце).
By October 1, 2021 more than 2 million of the 3,285,874 individuals living in Puerto Rico had completed theCOVID-19 vaccination series. Furthermore, since the start of the vaccination process to October 1, 2021,111,052 cases have been detected with molecular or antigen tests in Puerto Rico with two surges, one starting in late March after restrictions were lifted and another in late June with the arrival of the Delta variant. During the period considered in this analysis (December 15, 2020 to October 1, 2021), 87,399 laboratory-confirmed SARS-CoV-2 infections were observed for individuals 12 years or older.
Results All vaccines were effective at reducing risks for all outcomes across all age groups. At the peak of their protection, mRNA-1273, BNT162b2, and Ad26.COV2.S had an effectiveness of 87% (85% - 89%), 85% (82% - 87%), and 65% (58% - 70%), with Ad26.COV2.S reaching this peak 32 days after the being considered fully vaccinated. After four months, effectiveness waned to about 73%, 58%, and 32% for mRNA-1273, BNT162b2, and Ad26.COV2.S, respectively. All vaccines had a lower effectiveness for those over 85 years, with the decrease in effectiveness particularly low for the Ad26.COV2.S vaccine. We found no clear evidence that effectiveness was different after the Delta variant became dominant. For those infected, the vaccines provided further protection against hospitalization and deaths across all age groups, although the protection was less for those above 85 years. Using the rates observed for the unvaccinated we would have observed 6,109 and 2,071 hospitalizations and deaths among the vaccinated population but we instead observed 728 and 164, respectively. Conclusions The mRNA-1273 and BNT162b2 vaccines where highly effective across all age groups. They were still effective after four months although the protection did wain. The Ad26.COV2.S vaccine was effective but to a lesser degree, especially for the older age groups, and with the protection waning substantially sooner in comparison to the other two vaccines.
Спустя 4 месяца после прививки, защитная эффективность от болезни составляла уже 71%, 56%, и 27%, соответственно.
Менее всего прививка (любая, но слабее всех-джансен) защищала тех, кому более 85 лет.
При этом, все вакцины все же, более эффективно предотвращали госпитализацию (примерно в 9 раз, по сравнению с непривитыми) и смерть (примерно в 14 раз) от ковида, даже спустя 4 месяца после вакцинации. Данные цифры усреднены (актуальные цифры- в самой статье), тк джанссен показала чуть меньшую эффективность, и для более пожилых тоже защита чуть ниже.
Так же, с точки зрения авторов, защитная эффективность слабела не только потому, что было широкое распространение "дельты" (тк вначале доминирования дельты защита была выше чем в конце).
By October 1, 2021 more than 2 million of the 3,285,874 individuals living in Puerto Rico had completed theCOVID-19 vaccination series. Furthermore, since the start of the vaccination process to October 1, 2021,111,052 cases have been detected with molecular or antigen tests in Puerto Rico with two surges, one starting in late March after restrictions were lifted and another in late June with the arrival of the Delta variant. During the period considered in this analysis (December 15, 2020 to October 1, 2021), 87,399 laboratory-confirmed SARS-CoV-2 infections were observed for individuals 12 years or older.
Results All vaccines were effective at reducing risks for all outcomes across all age groups. At the peak of their protection, mRNA-1273, BNT162b2, and Ad26.COV2.S had an effectiveness of 87% (85% - 89%), 85% (82% - 87%), and 65% (58% - 70%), with Ad26.COV2.S reaching this peak 32 days after the being considered fully vaccinated. After four months, effectiveness waned to about 73%, 58%, and 32% for mRNA-1273, BNT162b2, and Ad26.COV2.S, respectively. All vaccines had a lower effectiveness for those over 85 years, with the decrease in effectiveness particularly low for the Ad26.COV2.S vaccine. We found no clear evidence that effectiveness was different after the Delta variant became dominant. For those infected, the vaccines provided further protection against hospitalization and deaths across all age groups, although the protection was less for those above 85 years. Using the rates observed for the unvaccinated we would have observed 6,109 and 2,071 hospitalizations and deaths among the vaccinated population but we instead observed 728 and 164, respectively. Conclusions The mRNA-1273 and BNT162b2 vaccines where highly effective across all age groups. They were still effective after four months although the protection did wain. The Ad26.COV2.S vaccine was effective but to a lesser degree, especially for the older age groups, and with the protection waning substantially sooner in comparison to the other two vaccines.